LevelStock.com: Cellceutix Completes Successful Pre-IND Meeting With FDA for Cancer Drug

Feb 16th 2010,  Braintree,Ma. LevelStock.com is pleased to announce to all of its members and investors information on  Cellceutix Corporation (OTCBB: CTIX).  The Company released news as follows:

Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, today announced that is has completed a successful pre-Investigational New Drug exemption (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead compound, Kevetrin, which is being developed to treat drug resistant cancers. The Company has the remaining pre-IND animal studies for Kevetrin underway. These studies consist of intermediate-term toxicity studies in two species and safety pharmacology studies in the cardiovascular, central nervous system and respiratory areas.

In animal studies, Kevetrin was found to significantly delay tumor growth in two multi-drug resistant lung cancer cell lines. In two experiments with the NCI-H1975 cell line, Kevetrin showed an average tumor growth delay of 149% compared to controls, while paclitaxel delayed tumor growth an average of 72%. The delay in Kevetrin treated animals was significantly greater than in the animals treated with paclitaxel (p < 0.01). In two experiments with the A549 cell line, Kevetrin showed an average tumor growth delay of 72% compared to controls while paclitaxel showed an average tumor growth delay of 6%. Again, the delay in Kevetrin treated animals was significantly greater than in the animals treated with paclitaxel (p < 0.01). Kevetrin has also shown promising results in animal studies of resistant breast and colon cancer.

“FDA provided some very helpful comments on our study protocols,” said George Evans, CEO of Cellceutix. “We have incorporated their comments and now have the remaining studies underway, after which we will be able to go forward with our IND filing. This would be a very significant milestone for Cellceutix.”

An audio link discussing this event is at:

http://www.cellceutix.com/news/press-release-audio-2-16-2010.html

About Cellceutix

Cellceutix Corporation is a preclinical cancer and anti-inflammatory drug developer. Cellceutix owns the rights to seven drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, and KM-133, which it is developing for the treatment of psoriasis. More information is available on the Cellceutix web site at www.cellceutix.com.

This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix’s actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.

The factors that may cause Cellceutix’s actual results to differ from its forward-looking statements include: Cellceutix’s current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix’s ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix’s SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.

Kevetrin has not been studied in humans at this time. The Company’s positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

About LevelStock.com

We are an investor community and investors relations website specializing in emerging growth stocks in today’s Hot Sectors and providing a platform of services for SmallCap, MicroCap, NanoCap Companies.

We encourage everyone to join our social media sites:

Free Subscription For Our Newsletters:  http://www.levelstock.com/

FaceBook: http://www.facebook.com/group.php?gid=283660480870

Twitter: http://twitter.com/levelstock

LevelStock.com is not a registered investment advisor or broker-dealer. The information here is believed to be reliable, but not guaranteed to be accurate by LevelStock.com Please be advised that the information contained may or may not be complete and is solely for informational purposes only. Please read our full disclaimer for complete risks and disclosures http://levelstock.bondwaresite.com/news.php?viewStory=19

CONTACT INFO: LevelStock.com 288 Grove Street Suite 181, Braintree, MA 02184

Email: support@levelstock.com

[Via http://hotpennystocknews.wordpress.com]

What Should You Avoid if You Have Psoriasis?

There are a number of different skin conditions that somebody can be enduring but one of the more challenging for them to handle is psoriasis. The excuse why psoriasis is such a hard skin condition is twofold. Initially, they aren’t able to really determine what it is that causes psoriasis to begin with, although they do understand the mechanisms that are behind the skin rashes and flaking that occurs. Another problem is because medical science is genuinely not able to remedy psoriasis, but there are a small number of things that can be achieved as a way to make it slightly bit better.

One of the interesting things about psoriasis is because although it doesn’t have an exact root problem, the’re a number of issues that can genuinely cause it to flare up. These range anywhere from emotional problems to environmental problems that could be at the source of your recent flare up. Here are a few things for you to avoid that are able to help you to avoid having an issue with this disease.

Strain – You would be surprised with a number of problems that tension can cause and psoriasis is certainly on that list. It can be hard to overcome strain, especially since the majority of us tend to lead lives that are rather vexing in the beginning. By studying to let the majority of the stress go, and handling what you can through a variety of different calming methods, you will be in an improved position to overcome psoriasis.

Outside Environmental Issues – The’re a number of problems that occur in the surroundings which can also cause our psoriasis to flare up. One of these problems is allergies, either in the kind of airborne allergies or through various chemical substances that are unnatural. Averting these to the best of our ability is surely going to go quite some distance in helping you to overcome and avoid having a psoriasis problem.

Itching and Scratching – One final thing that you are able to avoid is any kind of harm to your skin that might come through scratching it. At times, it might be hard for us to avoid scratching but if we are in a position to do so without damaging the skin, we may be able to avoid an issue with psoriasis. We should likewise avoid putting anything on the skin we have which can damage it and cause a corresponding problem.

Psoriasis Treatment Expert Michael Marenick offers more free information, help and advice just by visiting his website on Psoriasis Treatment or visit his blog for more detailed info.

[Via http://calppsoriasistreatmentz.wordpress.com]